Randomised clinical trial: the effect of baclofen in patients with gastro‐oesophageal reflux ‐ a randomised prospective study

Abstract

SUMMARY BackgroundBaclofen, a GABA B agonist, has been shown to reduce transient lower oesophageal sphincter relaxations (TLESRs), a major cause of gastrooesophageal reflux disease (GERD).

816 Acid-Based Parameters on pH-Impedance Testing Predict Symptom Improvement With Medical Management Better Than Impedance Parameters

“…Therefore, acid parameters intuitively drive symptom outcome from medical management, and it follows that the predictive value of testing subjects off antisecretory therapy would be higher compared with those on therapy, as the diagnostic yield is much higher off therapy. In recent years, baclofen, a gamma amino butyric acid B receptor agonist, has been implemented as an adjunct to reduce the frequency of reflux events to complement anti-secretory therapy (43)(44)(45). This agent could potentially augment medical management of reflux and improve symptomatic outcomes by reducing reflux events; however, baclofen was not utilized for medical management in our study cohort.…”

CPAP-Related Aerophagia: Awareness First!

“…First, it may be diffi cult to quantitate, and much work needs to be done to better defi ne and quantitate it in a validated way. Secondly, investigations are needed to evaluate how CPAP-related aerophagia causes individual GER 5 Currently, no data exist on how to best manage CPAP-induced aerophagia. Does lowering CPAP pressure, adding expiratory pressure release, or using auto-adjusting CPAP or bilevel PAP decrease aerophagia?…”

Clinical Case Report of PPI-refractory Gastro-Esophageal Reflux Disease (GERD) with Korean Medicine Treatment - A Focus on Evaluation of the Abdominal Examination

“…Prokinetics, such as dopamine-2 receptor antagonists (eg, metoclopramide and domperidone), and TLESR inhibitors such as gamma-aminobutyric acid-B receptor agonists (eg, baclofen), are helpful in patients with refractory GERD. Although baclofen decreases the symptoms in some patients, the symptomatic benefit remains poor in others (61)(62)(63).…”